Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00471224 · ClinicalTrials.gov registry record

A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product

A clinical trial of Siderosis, sponsored by Pfizer.

Completed
Registry status
16
Enrollment target
3
Study locations

NCT00471224 is a study of Siderosis that has completed, run by Pfizer. The registered enrollment target is 16 participants. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00471224, a study of Siderosis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
16 participants
Enrollment target
3
Study locations

Study Summary

This protocol intends to detail investigations necessary to evaluate the ocular safety of subjects enrolled in study A4321001 and who have received formulated Drug Product (Lot 8716-098).

Conditions Studied

Interventions

  • OTHER Observational Trial

Study Locations (3)

Massachusetts

  • Pfizer Investigational Site - Boston

North Carolina

  • Pfizer Investigational Site - Charlotte

Texas

  • Pfizer Investigational Site - Houston

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2007-06
Est. Completion 2008-11

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00471224

The ClinicalTrials.gov registry entry for NCT00471224 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Siderosis appearing as the primary indexed condition, and to 1 intervention - of which Observational Trial is the first listed.

NCT00471224 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT00471224 about?

NCT00471224 is a clinical study titled "A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product". This protocol intends to detail investigations necessary to evaluate the ocular safety of subjects enrolled in study A4321001 and who have received formulated Drug Product (Lot 8716-098).

What is the current status of trial NCT00471224?

This trial is currently completed. The enrollment target is 16 participants. The study started on 2007-06. Estimated completion is 2008-11.

What conditions does trial NCT00471224 study?

This clinical trial studies the following conditions: Siderosis.

What interventions are being tested in trial NCT00471224?

The interventions under investigation include: Observational Trial (OTHER).

Who is sponsoring clinical trial NCT00471224?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00471224 being conducted?

This trial has 3 study locations across Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.